CYB-005 / Cybin - LARVOL DELTA

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Businesswire) - "Announced grant of first U.S. Composition of Matter patent in support of its CYB005 phenethylamines program. Cybin is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System disorders and continues to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline."

Financing • CNS Disorders

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program (Businesswire) - "Cybin Inc...today announced that the United States Patent and Trademark Office ('USPTO') has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phenethylamines program...The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System ('CNS') disorders. In addition, the Company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists."

Patent • CNS Disorders